The following table summarizes the Company’s marketable securities held at September 30, 2026 (in thousands):


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Commercial paper	$	316,639	$	—	$	(695	)	$	315,944
Corporate notes		72,501		—		(172	)		72,329
U.S. Treasury securities		411,326		—		(2,404	)		408,922
U.S. Government securities		28,661		—		(163	)		28,498
Corporate equity securities		4,913		—		—			4,913
Total	$	834,040	$	—	$	(3,434	)	$	830,606

The following table summarizes the Company’s marketable securities held at December 31, 2025 (in thousands):


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Commercial paper	$	304,861	$	162	$	(64	)	$	304,959
Corporate notes		149,928		128		(10	)		150,046
U.S. Treasury securities		462,112		872		—			462,984
U.S. Government securities		26,673		23		—			26,696
Corporate equity securities		5,581		—		—			5,581
Total	$	949,155	$	1,185	$	(74	)	$	950,266

The amortized cost of marketable debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. At September 30, 2026 and December 31, 2025, the balance in accumulated other comprehensive (loss) income was comprised solely of activity related to marketable debt securities. There were no realized gains or losses recognized on the sale or maturity of marketable securities for the three or nine months ended September 30, 2026. During the three months ended September 30, 2025, Eli Lilly and Company, or Lilly, completed its acquisition of Verve Therapeutics, Inc., or Verve, and as a result, the Company received total proceeds of $5.7 million for its 546,970 shares of Verve. The sale resulted in a realized loss of $0.4 million, recorded in "Interest and other income (expense), net" in the Company's statements of operations and other comprehensive loss. There were no other realized gains or losses from the sale of marketable securities during the nine months ended September 30, 2025.

The Company holds debt securities of companies with high credit quality and has determined that there was no material change in the credit risk of any of its debt securities. The contractual maturity dates of all the investments are less than one year.